Medicare expands dialysis coverage, but pricing guardrails unclear
H.R. 4055 — Dialysis-Related Amyloidosis Treatment Act of 2025 · Filed by Brian Babin (R-TX) · 2 cosponsors · Introduced Jun 20, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill expands Medicare coverage to include treatments for dialysis-related amyloidosis (a protein-buildup disease affecting dialysis patients) that are FDA-approved. It requires Medicare to pay 100% of reasonable charges for these treatments when delivered in dialysis facilities, separate from the standard dialysis payment system. The bill takes effect immediately upon enactment.
Why we flagged it
The bill's operative mechanism is straightforward: it adds a new covered service category to Medicare and mandates separate payment at 100% of reasonable charges. This is a standard coverage-and-payment amendment, not a carve-out or immunity grant.
What the text implies
- 100% payment at 'reasonable charges' (not a capped prospective rate) may create pricing pressure if 'reasonable' is not tightly defined by CMS; dialysis providers may have incentive to bill aggressively for DRA treatments.
- Exclusion from renal dialysis prospective payment system means DRA treatments bypass the bundled payment model, potentially fragmenting care coordination and creating separate billing streams.
The full analysis lists 4 implications of this text.
Who stands to gain
dialysis facility operators (freestanding and hospital-based); manufacturers of FDA-approved DRA treatments; dialysis service providers